Streetbeat News

Products Services

AMGN

Amgen announced positive results from the Phase 2a COURSE trial for TEZSPIRE, indicating plans for Phase 3 development of tezepelumab in treating Chronic Obstructive Pulmonary Disease (COPD). James Bradner, EVP of R&D and CSO at Amgen, expressed optimism about tezepelumab's potential for COPD patients.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 9:30 pm

GORO

IONR

KALU

USAU

WS

Gold Resource (NYSE:GORO) reported Q1 sales with significant metal outputs and ongoing efficiency efforts. Worthington Steel (NYSE:WS) was recognized as a partner-level supplier by John Deere (NYSE:DE) for the 12th consecutive year. U.S. Gold (NASDAQ:USAU) announced a $4.9 million direct offering. Ioneer (NASDAQ:IONR) discussed progress at its Rhyolite Ridge lithium site, highlighting its contribution to America's critical minerals supply chain. Kaiser Aluminum (NASDAQ:KALU) declared a quarterly dividend of 77 cents per share.

Portfolio Pulse from Austin DeNoce

April 16, 2024 | 9:01 pm

PXMD

PaxMedica (PXMD) shares surged following an emergency request from the Ministry of Health of Malawi for access to IV suramin, indicating strong international interest in the company's product.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:34 pm

PXMD

PaxMedica, Inc. (NASDAQ: PXMD) has received an emergency request from the Ministry of Health of Malawi for IV suramin (PAX-101) to treat African sleeping sickness amid a drug shortage. The company, focusing on neurological disorders, has completed pivotal batches of PAX-101 and is in discussions with the FDA regarding the impact on its NDA submission plans. PaxMedica's engagement with the FDA also explores the potential for a Priority Review Voucher under the Neglected Tropical Disease program, aiming to ensure a steady supply of suramin.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:32 pm

CLNN

Clene's stock price increased following the announcement of positive Phase 2 VISIONARY-MS long-term extension study results at the 2024 American Academy of Neurology Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:25 pm

DTIL

Precision BioSciences (DTIL) has concluded its collaboration with Prevail Therapeutics, regaining control of three programs. The collaboration demonstrated the efficacy of ARCUS for gene excision and insertion. DTIL plans to continue developing these programs independently or with new partners. The company's key clinical priorities in Hepatitis B and Primary Mitochondrial Myopathy, along with its financial runway until the second half of 2026, remain unaffected.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:17 pm

MSOS

VRNOF

Darren Weiss commented on the cannabis industry in America, highlighting its domestic production and design, and its potential as a health opportunity. He expressed hope for a change in U.S. policy towards cannabis soon. The Cannabis Capital Conference offers live access for insights into the industry.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:08 pm

GRAM

MSOS

Laurie Holcomb highlights the global reach of their medical program, noting discussions with various countries in Europe and the Middle East. The company is open to exploring opportunities in other markets, indicating a potential for international expansion.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:06 pm

CURLF

MSOS

Matt Darin discusses the varying cannabis cultures across Europe and notes a growing support for cannabis legislation. The context was likely shared during the Cannabis Capital Conference, with a mention of how to access the conference for both existing and new subscribers.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:05 pm

BA

UAL

United Airlines Holdings has retained the option to convert additional Boeing Max 10 aircraft into Max 8 or Max 9 models as required, indicating flexibility in their fleet management strategy.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 8:04 pm